Isonicotinoyl-butanoic acid hydrazone derivatives as anti-tubercular agents: In-silico studies, synthesis, spectral characterization and biological evaluation

被引:0
|
作者
Mehak Saba Lone
Mohamad Mosa Mubarak
Syed Ayaz Nabi
Farhat Ramzan Wani
Shaista Amin
Sayima Nabi
Hadiya Amin Kantroo
Mohammed Samim
Syed Shafi
Shamim Ahmad
Zahoor Ahmad
Syed Ovais Rizvi
Kalim Javed
机构
[1] Jamia Hamdard,Department of Chemistry, School of Chemical and Life Sciences (SCLS)
[2] CSIR-Indian Institute of Integrative Medicine (CSIR-IIIM),Clinical Microbiology and PK/PD Division
[3] Academy of Scientific & Innovative Research (AcSIR),Department of Pharmaceutical Chemistry, School of Pharmaceutical Education and Research (SPER)
[4] Jamia Hamdard,Department of Pharmacology, School of Pharmaceutical Education and Research (SPER)
[5] Jamia Hamdard,undefined
[6] Aurigene Discovery Technologies Limited,undefined
[7] GDC Surankote,undefined
[8] Higher Education Department,undefined
来源
Medicinal Chemistry Research | 2023年 / 32卷
关键词
Hydrazones; Tuberculosis; Cytotoxicity; Molecular docking; ADME studies.;
D O I
暂无
中图分类号
学科分类号
摘要
A series of novel 4-(2-isonicotinoylhydrazono)-4-aroylbutanoic acid derivatives (3a-n) were designed, synthesized and characterized by 1H-NMR, 13C-NMR, and mass spectroscopic analyses. The synthesized compounds evaluated for anti-tubercular activity against various M. tb strains showed potent anti-tubercular activity with MIC = 1 µg/ml for 3a, 3b, 3i and 3j against both H37Ra and H37Rv M. tb strains. MBC demonstrated that the synthesized compounds showed good bacteriocidal effect against both H37Ra and H37Rv M. tb strains with equivalent MIC and MBC values. All the compounds were found moderately active against the INH-resistant clinical isolates of M. tb with MIC 64 µg/ml. The most active compounds of the series (3a, 3b and 3i) were evaluated as non-cytotoxic towards normal human cell lines. In-silico docking studies and binding interactions of the synthesized compounds and INH revealed binding affinity towards the active site of the protein target M. tb InhA complexed with NADH (PDB ID: 4DRE). Among the most active compounds, 3a exhibited better binding affinity of -7.798 kcal/mol as compared to standard, INH (−6.925 kcal/mol). Compound 3a displayed hydrogen bonding between nitrogen of the pyridine ring and NH of VAL 65 and aromatic hydrogen bonding with C = O of LYS 63. Both phenyl ring and pyridine ring of the compound 3a exhibited π-π stacking interactions with phenyl ring of PHE 41 and hydrogen bonding between carboxylic oxygen of compound 3a and SER 20. Physicochemical properties and pharmacokinetic profiling assessed for the synthesized compounds were found to follow Lipinski’s rule using Swiss ADME online prediction tools. These findings make them promising candidates for the future development of new anti-tubercular agents.
引用
收藏
页码:808 / 826
页数:18
相关论文
共 50 条
  • [1] Isonicotinoyl-butanoic acid hydrazone derivatives as anti-tubercular agents: In-silico studies, synthesis, spectral characterization and biological evaluation
    Lone, Mehak Saba
    Mubarak, Mohamad Mosa
    Nabi, Syed Ayaz
    Wani, Farhat Ramzan
    Amin, Shaista
    Nabi, Sayima
    Kantroo, Hadiya Amin
    Samim, Mohammed
    Shafi, Syed
    Ahmad, Shamim
    Ahmad, Zahoor
    Rizvi, Syed Ovais
    Javed, Kalim
    MEDICINAL CHEMISTRY RESEARCH, 2023, 32 (05) : 808 - 826
  • [2] Chroman-Schiff base derivatives as potential Anti-Tubercular Agents: In silico studies, Synthesis, and Biological evaluation
    Mujeeb, Samar
    Singh, Kuldeep
    Al-Zrkani, Martha K.
    Al-Fahad, Dhurgham
    Hasan, Syed Misbahul
    Al Shouber, Marwah
    Ahmad, Fuzail
    Hameed, Husian Njem
    Iqbal, Danish
    Kamal, Mehnaz
    BIOORGANIC CHEMISTRY, 2025, 157
  • [3] Synthesis and biological evaluation of novel 1,2,3-triazole derivatives as anti-tubercular agents
    Ali, Abdul Aziz
    Gogoi, Dhrubajyoti
    Chaliha, Amrita K.
    Buragohain, Alak K.
    Trivedi, Priyanka
    Saikia, Prakash J.
    Gehlot, Praveen S.
    Kumar, Arvind
    Chaturvedi, Vinita
    Sarma, Diganta
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2017, 27 (16) : 3698 - 3703
  • [4] Discovery of New Isoniazid Derivatives As Anti-tubercular Agents: In silico Studies, Synthesis, and In vitro Activity Evaluation
    Mohd, Abida Ash
    Imran, Mohd
    Alnaser, Noura Yousif
    Altimyat, Shams Saud
    Al-otaibi, Nawaf M.
    Bawadekji, Abdulhakim
    ORIENTAL JOURNAL OF CHEMISTRY, 2023, 39 (06) : 1510 - 1520
  • [5] Synthesis, characterization, drug likeliness and biological activity of imidazopyridine derivatives as anti-tubercular agents
    Jain, Surabhi
    Sen, Dhrubo Jyoti
    INDIAN JOURNAL OF CHEMISTRY, 2022, 61 (03): : 305 - 312
  • [6] In-silico Molecular Docking and ADME/Pharmacokinetic Prediction Studies of Some Novel Carboxamide Derivatives as Anti-tubercular Agents
    Abdullahi, Mustapha
    Adeniji, Shola Elijah
    CHEMISTRY AFRICA-A JOURNAL OF THE TUNISIAN CHEMICAL SOCIETY, 2020, 3 (04): : 989 - 1000
  • [7] In-silico Molecular Docking and ADME/Pharmacokinetic Prediction Studies of Some Novel Carboxamide Derivatives as Anti-tubercular Agents
    Mustapha Abdullahi
    Shola Elijah Adeniji
    Chemistry Africa, 2020, 3 : 989 - 1000
  • [8] Indole Derivatives as Anti-Tubercular Agents: An Overview on their Synthesis and Biological Activities
    Reddy, Gangireddy Sujeevan
    Pal, Manojit
    CURRENT MEDICINAL CHEMISTRY, 2021, 28 (22) : 4531 - 4568
  • [9] Exploration of green catalytic Hantzsch process for synthesis of polyhydroquinoline derivatives and their in silico & in vitro evaluation as anti-tubercular agents
    Savale, Tulshidas S.
    Joshi, Nachiket
    Rao, G. S. N. Koteswara
    Mathure, Savita M.
    Chobe, Santosh S.
    More, Rahul A.
    Budha, Roja Rani
    Alavala, Rajasekhar Reddy
    JOURNAL OF MOLECULAR STRUCTURE, 2025, 1320
  • [10] Synthesis, Docking Studies, and Biological Evaluation of Betti Bases as Promising Anti-tubercular Agents
    Acharya, Poornima
    Ramana, Mucheli Muni Venkata
    Korgavkar, Nilesh
    Pavale, Ganesh
    Upadhyay, Manish
    LETTERS IN DRUG DESIGN & DISCOVERY, 2023, 20 (06) : 724 - 737